Kostev Karel, Doege Corinna, Jacob Louis, Smith Lee, Koyanagi Ai, Gollop Celina, Schrag Anette
University Clinic, Philipps University, 35043 Marburg, Germany.
Epidemiology, IQVIA, 60549 Frankfurt, Germany.
Brain Sci. 2023 Mar 6;13(3):450. doi: 10.3390/brainsci13030450.
The aim of this study was to analyze whether prescriptions of antiepileptic drugs (AEDs) are significantly associated with an increased incidence of Parkinson's disease (PD) in the German population.
This study used data from German primary care practices found in the Disease Analyzer database (IQVIA) and included all patients aged ≥18 years who were diagnosed with PD between January 2010 and December 2021 (index date). The controls were patients without PD matched (1:1) by age, sex, and pre-diagnostic observation time in years. Associations between AED prescriptions (any AED as well as separate evaluations for carbamazepine, lamotrigine, levetiracetam, sodium valproate, gabapentin, and pregabalin) and subsequent diagnosis of PD were examined using a logistic regression model adjusted for epilepsy, restless legs syndrome, and neuropathy diagnoses.
We identified 24,950 cases that were matched with 24,950 controls (mean age 75.2 years, 47.3% women). Diagnoses of epilepsy, restless legs syndrome, and neuropathy as well as AED prescription were significantly associated with an increased incidence of PD. In the multivariate analysis, incidence of PD was significantly associated with epilepsy (OR: 1.91; 95% CI: 1.69-2.15), restless legs syndrome (OR: 3.02; 95% CI: 2.73-3.34), and neuropathy (OR: 1.53; 95% CI: 1.44-1.62)), as well as the prescription of any AED (OR: 1.43; 95% CI: 1.33-1.53), sodium valproate (OR: 2.39; 95% CI: 1.84-3.11), gabapentin (OR: 1.36; 95% CI: 1.22-1.52), and pregabalin (OR: 1.28; 95% CI: 1.15-1.41) Conclusion: Prescriptions of AEDs, including sodium valproate, gabapentin, and pregabalin, were associated with an increased risk of subsequent PD, even after adjustment for underlying diagnoses. Further studies are needed to confirm the present results.
本研究旨在分析抗癫痫药物(AEDs)的处方是否与德国人群中帕金森病(PD)发病率的增加显著相关。
本研究使用了疾病分析器数据库(IQVIA)中德国初级医疗实践的数据,纳入了2010年1月至2021年12月期间(索引日期)所有年龄≥18岁且被诊断为PD的患者。对照组为无PD的患者,按年龄、性别和以年为单位的诊断前观察时间进行1:1匹配。使用针对癫痫、不宁腿综合征和神经病变诊断进行调整的逻辑回归模型,研究AED处方(任何AED以及对卡马西平、拉莫三嗪、左乙拉西坦、丙戊酸钠、加巴喷丁和普瑞巴林的单独评估)与后续PD诊断之间的关联。
我们确定了24950例病例,并与24950名对照匹配(平均年龄75.2岁,女性占47.3%)。癫痫、不宁腿综合征和神经病变的诊断以及AED处方与PD发病率的增加显著相关。在多变量分析中,PD发病率与癫痫(比值比:1.91;95%置信区间:1.69 - 2.15)、不宁腿综合征(比值比:3.02;95%置信区间:2.73 - 3.34)和神经病变(比值比:1.53;95%置信区间:1.44 - 1.62)以及任何AED的处方(比值比:1.43;95%置信区间:1.33 - 1.53)、丙戊酸钠(比值比:2.39;95%置信区间:1.84 - 3.11)、加巴喷丁(比值比:1.36;95%置信区间:1.22 - 1.52)和普瑞巴林(比值比:1.28;95%置信区间:1.15 - 1.41)显著相关。结论:即使在对潜在诊断进行调整后,包括丙戊酸钠、加巴喷丁和普瑞巴林在内的AED处方与后续发生PD的风险增加相关。需要进一步研究来证实目前的结果。